Safety monitoring and information
Understand the ways we work to ensure medicines and medical devices remain as safe and effective as possible. Access information on product safety topics.
This page is in Beta testing. We welcome your feedback and suggestions as we look to improve this page.
What safety means
Safety is determined by weighing the known and potential risks, against the expected benefits when a therapeutic good is used as intended. While some risks are identified during the approval process, others may only become apparent after broader use.
The safety of therapeutic goods is a shared responsibility between regulators, sponsors, healthcare professionals and consumers.
How we monitor safety
We monitor safety through a range of different activities:
- Pre-market evaluation: Products must meet strict safety, quality and efficacy standards before being included in the Australian Register of Therapeutic Goods (ARTG).
- Post-market surveillance: We monitor products once they are on the market through adverse event reports, product testing, recalls and safety reviews.
- Adverse event reporting: Anyone can report adverse events or side effects, product defects or safety concerns. These reports help identify emerging risks and inform regulatory action.
- Product testing and investigations: Our laboratories test therapeutic goods to ensure they meet Australian standards and compare results with international benchmarks. See further information on our Product testing and investigations.
- Recalls and market actions: If a safety issue is identified, we may initiate recalls, issue safety alerts or require product corrections.
A key activity in safety monitoring is identifying patterns that emerge when problems are reported by sponsors, health professionals and consumers. An adverse event occurring does not necessarily mean that there is something wrong with a therapeutic good. However, each report helps to build a picture of the safety profile of a product. You can Report an adverse event or safety problem.
Latest alerts
-
Medifab is conducting a product correction for the KayserBetten Safe Surround Genie Bed.
-
Consumers are advised that the medicines listed below containing Andrographis paniculata (Andrographis) are being recalled due to the risk of severe allergic reactions.
-
Retatrutide products marketed for weight loss may pose a serious risk to your health and should not be used.
Latest articles
-
Vaccine reconstitution
Health care professionals should check product-specific instructions when preparing and administering vaccines. -
TGA seeks public views on stronger vitamin B6 labelling for low-risk medicines
We seeking feedback on a proposal to strengthen the labelling of low-risk products that contain vitamin B6. -
Improvements to monthly Product Information updates
We have improved the way we present our Product Information (PI) safety updates to help you find the information you need.
Latest publications
-
TGA Laboratories has released a report describing our assessment of the 2026 seasonal flu vaccine
-
Communique from the 13th meeting of the Women's Health Products Working Group, 16 July 2026.
-
This report summarises the outcomes of the Pharmacovigilance Inspection Program in the 2-year period. The deficiencies identified are presented along with case studies of critical deficiencies from this reporting period, to support medicine sponsors in the continual improvement of their pharmacovigilance systems.
Open consultations
-
Consultation: High-moderate risk changes to permissible ingredients - Vitamin B6 (pyridoxine hydrochloride, pyridoxal 5-phosphate, and pyridoxal 5-phosphate monohydrate)
The Therapeutic Goods Administration (TGA) is seeking public comment on proposed changes to the Therapeutic Goods (Permissible Ingredients) Determination relating to listed medicines containing vitamin B6, namely pyridoxine hydrochloride, pyridoxal 5-phosphate and pyridoxal 5-phosphate monohydrate.